Cardiovascular risk factors are rewriting the timeline for dementia prevention. Evidence shows brain changes begin decades before symptoms appear.
Research presented this week at a major international symposium in Madrid confirms that atherosclerosis and metabolic alterations appear in seemingly healthy people around age 50 — long before clinical cardiovascular disease emerges. The findings shift the prevention window earlier and position vascular health as a modifiable lever for cognitive preservation.
For decades, neurodegenerative research focused on neurons and protein accumulation — amyloid beta and tau in Alzheimer’s disease. That view is changing.
The neurovascular network, encompassing cerebral blood flow, the blood-brain barrier, waste clearance systems, and systemic biology including the microbiota, is now recognized as essential to cognitive function across the lifespan.
“We now know that neurons do not function in isolation. Brain health depends on a constant interaction between neurons, vascular cells, immune cells and multiple mechanisms of protection and maintenance, as well as systemic influences, including the role of the microbiota,” said Dr. María Ángeles Moro, coordinator of the Cardiovascular and Brain Health Program at Spain’s National Center for Cardiovascular Research (CNIC).
This perspective positions dementia not as a single mechanism but as a convergence of neurodegenerative and vascular processes that amplify each other. Small vessel disease, microthrombosis in Alzheimer’s, and impaired glymphatic clearance are increasingly documented as interconnected pathways.
MRI Composite Links Cardiovascular Risk to Glymphatic Decline and Cognition
A study of 92 older adults, with 68 reassessed at six months, constructed an MRI-derived glymphatic composite from six measures: choroid plexus volume and free-water fraction, DTI-ALPS index along perivascular spaces, BOLD-CSF coupling, and perivascular spaces in basal ganglia and deep white matter. Higher 10-year cardiovascular risk scores correlated with less favorable glymphatic profiles at both time points.
The composite also mediated the relationship between cardiovascular risk and poorer performance on executive function tasks. Participants with higher risk showed reduced cortical thickness in Alzheimer’s-vulnerable regions, and the glymphatic composite explained part of that association. The findings replicated in the six-month follow-up cohort.
Healthy Sleep Attenuates Cardiometabolic Damage to Brain Structure
In a separate analysis of 408,977 UK Biobank participants, 13.2% had at least one cardiometabolic disease — type 2 diabetes, heart disease, or stroke. Among those with disease, a healthy sleep pattern was associated with significantly better global cognition, verbal reasoning, and processing speed compared to poor sleepers.
Neuroimaging in a subsample of 34,913 showed that healthy sleepers with cardiometabolic disease had larger total brain, gray matter, and white matter volumes. The sleep composite incorporated duration, chronotype, insomnia symptoms, snoring, and daytime sleepiness.
Modifiable Factors Offer Prevention Window Decades Before Symptoms
“We have increasing evidence that the processes leading to dementia begin years before their clinical manifestations. Cardiovascular risk factors and atherosclerosis can be detected and, in many cases, modified decades before the onset of symptoms,” said Dr. Valentín Fuster, director general of CNIC.
Controlling high blood pressure, diabetes and cholesterol, avoiding smoking and maintaining a physically active life not only protects the cardiovascular system, but also brain health. Fuster added
The 2024 Lancet Commission update identified 14 modifiable risk factors for dementia, though oral health was not included despite emerging evidence. The commission’s findings underpin new WHO guidelines on dementia risk reduction published this year.
Dr. María Ángeles Moro graduated in Pharmacy at Universidad de Alcalá and earned a PhD in Pharmacology at Universidad Autónoma de Madrid in 1990. After a postdoctoral fellowship at Wellcome Research Laboratories in the UK from 1991 to 1995, she became a Full Professor of Pharmacology at Universidad Complutense de Madrid before joining CNIC in November 2019 to lead the Neurovascular Pathophysiology Group.
She also co-leads the Neurovascular Diseases Group at the Hospital Health Institute “12 de Octubre” (i+12) and participates in consortia including the Spanish Neurovascular Network (INVICTUS) and the Leducq Foundation Grant “Stroke-Impact.”
International Collaboration Targets Neurovascular Prevention Strategies
The 2nd International Symposium ‘Understanding the Neurovascular Network to Prevent Dementia,’ organized by CNIC and the Ramón Areces Foundation, brought together researchers including Joanna Wardlaw and Anne Joutel on cerebral small vessel disease, and CNIC’s Marta Cortés Canteli on microthrombosis in Alzheimer’s.
The meeting highlighted a shift: prevention strategies must target the vascular system as aggressively as neuronal pathways. This approach emphasizes that protecting the brain’s blood vessels is essential for reducing the overall risk of developing dementia.